Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 first-quarter earnings
what-you-need-to-know-about-johnson-and-johnsons-2022-first-quarter-earnings-lede.png

What you need to know about Johnson & Johnson’s 2022 first-quarter earnings

Check out this infographic breakdown of the company’s first-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

q1-2022-quarterlyearnings-0422.png

This morning, Johnson & Johnson shared its first-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Even in the face of some macro-economic headwinds, Johnson & Johnson posted strong results for the quarter, continuing to deliver reliable growth and investing to advance our pipeline. We’re proud to announce a dividend increase for the 60th consecutive year, a key capital allocation priority. We remain well positioned to accelerate innovation as we evolve into a smarter era of healthcare, and work to successfully stand up the New Consumer Health Company,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson.

For more details about the company’s 2022 first-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


An infographic showing key stats about Johnson & Johnson's first-quarter 2022 earnings

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.